GlassScriptPhysician profile
Madeleine C Weiser
NPI 1497725881
$2,663.00
in general payments reported to CMS, 2019-2025
21 companies · $39.34 in 2025
The $39.34 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $341 · 2021: $382 · 2022: $900 · 2023: $34.89 · 2024: $106 · 2025: $39.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $881.98 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $249.36 | 2019-2022 | |
| Kaleo, INC. | $246.03 | 2019-2023 | Auvi-Q |
| Neos Therapeutics, LP | $245.45 | 2020-2022 | |
| Tris Pharma INC | $242.85 | 2019-2022 | |
| Corium, LLC | $235.05 | 2022-2024 | Azstarys |
| Glaxosmithkline, LLC. | $108.92 | 2020-2023 | Bexsero |
| Adlon Therapeutics L.P. | $97.42 | 2020-2021 | |
| Pfizer INC. | $59.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.93 | 2019-2020 | |
| Genentech USA, INC. | $43.55 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $39.34 | 2025 | Jornay Pm |
| Shire North American Group INC | $36.39 | 2019 | |
| Sobi, INC | $21.99 | 2022 | |
| Sanofi Pasteur INC. | $18.71 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $17.55 | 2021 | |
| Hologic Sales and Service, LLC | $16.11 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.86 | 2021 | |
| Aytu Biopharma, INC. | $14.40 | 2024 | Karbinal |
| Merck Sharp & Dohme LLC | $12.82 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madeleine Weiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.